Product Theaters
Saturday, December 11
11:30 a.m.-12:30 p.m.
Theater 1
In-Person Participants Only
A Treatment Option for Adults With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After At Least Two Prior Lines of Systemic Therapy*
Sponsored by: Bristol Myers Squibb
Speaker: Mecide Gharibo, MD, Vice President, U.S. Medial Affairs Hematology, Bristol Myers Squibb
Theater 2
In-Person Participants Only
IMBRUVICA® (ibrutinib) Long Term Efficacy and Safety Clinical Trial Data
Sponsored by: Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Speaker: James Dean, MD, PhD, Global Development Lead, Imbruvica Oncology Development, Pharmacyclics LLC, an AbbVie Company
Theater 3
In-Person Participants Only
AYVAKIT: Now approved for advanced systemic mastocytosis*
Sponsored by: Blueprint Medicines
Speaker: Robyn M. Scherber, MD, MPH, Senior Medical Director, Blueprint Medicines
Theater 4
Evolving CLL Treatment Paradigm
Sponsored by: AbbVie
Speaker: R. Frank Cornell, MD, MS, Medical Director, U.S. Medical Affairs, AbbVie
Theater 5
Study Design for Anemia of MDS and Chemotherapy Induced Anemia
Sponsored by: AstraZeneca
Speaker: Katharina Modelska, MD, PhD, FibroGen
Theater 6
In-Person Participants Only
BLENREP (belantamab mafodotin-blmf) for Injection 100mg (Includes 6-Month Clinical Data and Updated Data From 13-Month Follow-Up)*
Sponsored by: GSK
Speaker: Ira Gupta, MD, Vice President, Medicine Development Leader, GSK
*Presentation is intended for U.S.-based registered meeting attendees
Sunday, December 12
8:00-9:00 a.m.
Theater 1
A Treatment Option for Patients with Myelodysplastic Syndromes
Sponsored by: Bristol Myers Squibb Speaker: Christina Hughes, PhD, Director, WW Medical Affairs, Hematology Myeloid, Bristol Myers Squibb
Theater 2
Rare Bleeding Disorders in Girls and Women: The Use of a rFVIIa Product
Sponsored by: Novo Nordisk
Speakers: Stephanie Seremetis, MD, CVP and Chief Medical Officer, Bio- pharm, Novo Nordisk
Theater 3
In-Person Participants Only
An Effective Oral TPO-RA: DOPTELET® (avatrombopag) for Adult Patients With Chronic Immune Thrombocytopenia (ITP)
Sponsored by: Sobi
Speaker: Scott Kolodny, MD, Senior Director, North American Medical Affairs, Sobi
Sunday, December 12
11:30 a.m.-12:30 p.m.
Theater 1
In-Person Participants Only
Pivotal Phase 3 Data in Newly Diagnosed AML: Exploring the Efficacy, Safety, and Patient Management of Evolving AML Treatment Paradigms*
Sponsored by: Genentech
Speaker: Grace Ku, MD, Global Development Leader- Venetoclax Myeloid, Multiple Myeloma, Pediatrics, Genentech
Theater 2
The Time Is Now: Evidence for Actionability of clonoSEQ MRD Assessment in Lymphoid Cancer Patient Care*
Sponsored by: Adaptive Biotechnologies
Speaker: Allison Jacob, Medical Director, clonoSEQ, Adaptive Biotechnologies
Theater 3
In-Person Participants Only
Evolving Treatment Approaches in MDS & CMML
Sponsored by: Taiho Oncology
Speaker: Harold Keer, MD, PhD, Chief Medical Officer, Taiho Oncology/Astex Pharmaceuticals
Theater 4
The Increasing Reach of CAR T-cell therapy: The Kite Story Sponsored by: Kite, a Gilead Company
Speakers: Warner Biddle, Senior Vice President, Global Head of Commercial, Kite, a Gilead Company; Frank Neumann, Senior Vice President, Global Head of Clinical Development, Kite, a Gilead Company; Charles Calderaro, Senior Vice President, Global Head of Technical Operations, Kite, a Gilead Company
Theater 5
Haematology R&D at AstraZeneca; Novel Strategies, Targets, and Treatment for Blood
Sponsored by: AstraZeneca
Speakers: Raoul Tibes, MD, Global Head Leukemia Strategy & Clinical Development, AstraZeneca; Robert Chen, MD, Global Head of Lymphoma Clinical Development and Strategy, AstraZeneca; Simon Rule, MD, Global Head of Calquence, AstraZeneca
Theater 6
In-Person Participants Only
A Treatment Option for Adult Patients With Newly Diagnosed CP Ph+ CML or Patients With CML Resistant/Intolerant to Prior TKI Therapy
Sponsored by: Pfizer Inc.
Speaker: Erinn Hoag Goldman, PhD, Medical Director, Hematology, U.S. Medical Affairs, Pfizer Inc.
Virtual Meeting Platform Only
Importance of Sustained Terminal Complement Inhibition in PNH
Sponsored by: Alexion Pharmaceuticals Inc.
Speaker: Anita Hill, MD, PhD, Global Medical Affairs Lead Haematology & Nephrology and Consultant for Clinical Development, Alexion Pharmaceuticals Inc.
*Presentation is intended for U.S.-based registered meeting attendees
Monday, December 13
8:00-9:00 a.m.
Theater 1
A Treatment Option for Patients with Acute Myeloid Leukemia
Sponsored by: Bristol Myers Squibb
Speaker: Ali McBride, Director Hematology HEOR, Bristol Myers Squibb
Monday, December 13
12:15-1:15 p.m.
Theater 1
ZYNLONTA® (loncastuximab tesirinelpyl), the First-and-Only CD19-Targeted ADC, for the Treatment
of Adults with R/R DLBCL After Two or More Lines of Systemic Therapy
Sponsored by: ADC Therapeutics
Speaker: Joseph Camardo, MD, Chief Medical Officer, ADC Therapeutics
Theater 2
In-Person Participants Only
Case Study: A 19-Year-Old Female With Distal Radius Fracture and Anemia
Sponsored by: Agios
Speakers: Amber Yates, MD, FAAP, Medical Director, Agios; Felix Chapovsky, MD, Medical Director, Agios
Theater 3
In-Person Participants Only
Cytopenic Myelofibrosis and an Introduction to Pacritinib*
Sponsored by: CTI BioPharma Corp.
Speaker: Sarah Buckley, MD, Senior Medical Director, CTI BioPharma Corp.
Theater 4
In-Person Participants Only
Discussion in the Treatment of Sickle Cell Disease, Moving Beyond Pain As a Primary Target
Sponsored by: Global Blood Therapeutics
Speaker: Kim Smith-Whitley, MD, Executive Vice President, Head of Research and Development, Global Blood Therapeutics
Theater 5
In Adult and Pediatric Patients 12 Years and Older with Chronic GVHD, Intervene with Jakafi® (ruxolitinib) At the First Sign of Initial Systemic Treatment Failure
Sponsored by: Incyte
Speaker: John P Galvin MD, MPH, MS, Senior Medical Director, Graft versus Host Disease, Incyte, Assistant Professor, University of Illinois Chicago
Theater 6
In-Person Participants Only
Redefining Frontline Therapy in Transplant Ineligible Multiple Myeloma Patients: MAIA 5-year Update including Overall Survival
Sponsored by: Janssen Biotech
Speaker: Thomas Lin, MD, PhD, Head of Multiple Myeloma, U.S. Medical Affairs, Janssen Oncology
Theater 7
A Breakthrough in aTTP Treatment
Sponsored by: Sanofi Genzyme
Speaker: Rui De Passos Sousa, MD, Global Medical Head - TTP, ITP and Pemphigus, Sanofi Genzyme
*This presentation is intended for U.S.-based registered meeting attendees
Industry Theaters
Saturday, December 11
11:30 a.m.-12:30 p.m.
Theater 7
Pfizer’s Leadership Through Science: Driving Innovation in Hematology*
Sponsored by: Pfizer Inc.
Speakers: Andy Schmeltz, Global President & General Manager, Pfizer Oncology; Dany Habr, MD, Chief Medical Officer, Pfizer Oncology; Vali Papadimitrakopoulou, MD, Vice President, Head of Clinical Development, Global Product Development, Pfizer Oncology
Sunday, December 12
11:30 a.m.-12:30 p.m.
Theater 7
Immune System Unleashed: Leveraging the Innate Immune System in HR-MDS
Sponsored by: Gilead Sciences
Speaker: Carol O’Hear, MD, PhD, Vice President, Oncology Clinical Development, Gilead Sciences
Company Showcases
Saturday, December 11
1:30-1:45 p.m.
Theater 5
In-Person Participants Only
Emerging Standard Single Cell Functional Biomarkers of Immune Function and Potency, and Duomic, a Novel Simultaneous Single Cell Transcriptomics and Functional Proteomics Platform to Transform Connected Therapeutic Biology
Sponsored by: IsoPlexis
Speaker: Chase Migliore, Proteomics Specialist, IsoPlexis
Theater 6
Genetic Therapy in Hemoglobinopathies
Sponsored by: Vertex Pharmaceuticals
Speaker: William Hobbs, MD, PhD, Vice President, Clinical Development, Hematology, Vertex Pharmaceuticals
Theater 7
In-Person Participants Only
Duplex Sequencing for Ultra-Low Frequency Measurable Residual Disease Detection
Sponsored by: TwinStrand Biosciences Speakers: Jesse Salk, MD, PhD, Chief Executive Officer, TwinStrand Biosciences; Jake Higgins, PhD, Senior Scientist, TwinStrand Biosciences
Virtual Meeting Platform Only
UCB Showcase of Commitment to Patients With ITP
Sponsored by: UCB Biopharma
Speaker: Donatello Crocetta, MD, MBA, Head of Medical Affairs, Rare Diseases, UCB Biopharma
Sunday, December 12
4:00-4:15 p.m.
Theater 7
In-Person Participants Only
Introduction to Alnylam Pharmaceutical and a Treatment Option for Adults with Acute Hepatic Porphyria Featuring 24-month data from the ENVISION Open-Label Extension (OLE) Study
Sponsored by: Alnylam Pharmaceuticals
Speaker: Laurent Placidi, PharmD, PhD, Program Lead, Acute Hepatic Porphyria, Alnylam Pharmaceuticals
Monday, December 13
10:00-10:15 a.m.
Theater 7
Unleashing the Power of Single-Cell Multimodal Analysis to Advance Precision Medicine
Sponsored by: Mission Bio
Speaker: Aaron Llanso, Director of Translational Application and Market Development, Mission Bio
Virtual Meeting Platform Only
The Syros Clinical Stage Pipeline in Targeted Hematology Therapies. Overview of Novel Small Molecule Gene Control Medicines in Development for MDS, AML, APL and NHL
Sponsored by: Syros
Speaker: David Roth, MD, Chief Medical Officer, Syros
